Occurrence, risk factors and outcome of adenovirus infection in adult recipients of allogeneic hematopoietic stem cell transplantation

Journal of Clinical Virology

Volumn 82, Issue , 2016, Pages 33-40

  Hubmann, Max ^a   Fritsch, Susanne ^a   Zoellner, Anna Katharina ^a   Prevalsek, Dusan ^a   Engel, Nicole ^a   Bücklein, Veit ^a   Mumm, Friederike ^a   Schulz, Christoph ^a   Stemmler, Hans Joachim ^a   Jäger, Gundula ^b   Ledderose, Georg ^a   Kolb, Hans Jochem ^b   Hausmann, Andreas ^a,d   Hiddemann, Wolfgang ^a   Moosmann, Andreas ^c   Tischer, Johanna ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d Klinikum Schwabing   (Germany)

Author keywords

Adenovirus; Allogeneic hematopoietic stem cell transplantation; Alternative donor transplantation; Disseminated disease

Indexed keywords

ALEMTUZUMAB; CIDOFOVIR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLATE MOFETIL; RAPAMYCIN; RIBAVIRIN; TACROLIMUS; THYMOCYTE ANTIBODY; ANTIVIRUS AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ADENOVIRUS INFECTION; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALTERNATIVE DONOR TRANSPLANTATION; ANTIVIRAL THERAPY; ARTICLE; CELL SPECIFICITY; DISEASE COURSE; DRUG MEGADOSE; FEMALE; GRAFT RECIPIENT; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; T LYMPHOCYTE; TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TREATMENT RESPONSE; VIRAL CLEARANCE; YOUNG ADULT; ADOLESCENT; AGED; ALLOTRANSPLANTATION; COMPLICATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOCOMPROMISED PATIENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADENOVIRIDAE INFECTIONS; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84978859507     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2016.07.002     Document Type: Article

References (45)

1. [1] Tomblyn, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface Bone Marrow Transplant. 44 (2009), 453–455.
2. [2] Lion, T., Baumgartinger, R., Watzinger, F., Matthes-Martin, S., Suda, M., Preuner, S., et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 102 (2003), 1114–1120.
3. [3] Chakrabarti, S., Mautner, V., Osman, H., Collingham, K.E., Fegan, C.D., Klapper, P.E., et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 100 (2002), 1619–1627.
4. [4] La Rosa, A.M., Champlin, R.E., Mirza, N., Gajewski, J., Giralt, S., Rolston, K.V., et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin. Infect. Dis. 32 (2001), 871–876.
5. [5] Robin, M., Marque-Juillet, S., Scieux, C., Peffault de Latour, R., Ferry, C., Rocha, V., et al. Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome. Haematologica 92 (2007), 1254–1257.
6. [6] Chakrabarti, S., Collingham, K.E., Fegan, C.D., Pillay, D., Milligan, D.W., Adenovirus infections following haematopoietic cell transplantation: is there a role for adoptive immunotherapy. Bone Marrow Transplant. 26 (2000), 305–307.
7. [7] Heemskerk, B., Lankester, A.C., van Vreeswijk, T., Beersma, M.F., Claas, E.C., Veltrop-Duits, L.A., et al. Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients. J. Infect. Dis. 191 (2005), 520–530.
8. [8] Ballen, K.K., Koreth, J., Chen, Y.B., Dey, B.R., Spitzer, T.R., Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood 119 (2012), 1972–1980.
9. [9] Ruggeri, A., Peffault de Latour, R., Carmagnat, M., Clave, E., Douay, C., Larghero, J., et al. Outcomes, infections, and immune reconstitution after double cord blood transplantation in patients with high-risk hematological diseases. Transpl. Infect. Dis. 13 (2011), 456–465.
10. [10] Ljungman, P., Ribaud, P., Eyrich, M., Matthes-Martin, S., Einsele, H., Bleakley, M., et al. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 31 (2003), 481–486.
11. [11] Leen, A.M., Christin, A., Myers, G.D., Liu, H., Cruz, C.R., Hanley, P.J., et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 114 (2009), 4283–4292.
12. [12] Hromas, R., Cornetta, K., Srour, E., Blanke, C., Broun, E.R., Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood 84 (1994), 1689–1690.
13. [13] Taniguchi, K., Yoshihara, S., Tamaki, H., Fujimoto, T., Ikegame, K., Kaida, K., et al. Incidence and treatment strategy for disseminated adenovirus disease after haploidentical stem cell transplantation. Ann. Hematol. 91 (2012), 1305–1312.
14. [14] Feuchtinger, T., Matthes-Martin, S., Richard, C., Lion, T., Fuhrer, M., Hamprecht, K., et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br. J. Haematol. 134 (2006), 64–76.
15. [15] Feucht, J., Opherk, K., Lang, P., Kayser, S., Hartl, L., Bethge, W., et al. Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood 125 (2015), 1986–1994.
16. [16] Schmid, C., Schleuning, M., Ledderose, G., Tischer, J., Kolb, H.J., Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J. Clin. Oncol. 23 (2005), 5675–5687.
17. [17] Schmid, C., Schleuning, M., Schwerdtfeger, R., Hertenstein, B., Mischak-Weissinger, E., Bunjes, D., et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 108 (2006), 1092–1099.
18. [18] Tischer, J., Stemmler, H.J., Engel, N., Hubmann, M., Fritsch, S., Prevalsek, D., et al. Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia. Ann. Hematol. 92 (2013), 1379–1388.
19. [19] Tischer, J., Engel, N., Fritsch, S., Prevalsek, D., Hubmann, M., Schulz, C., et al. Second haematopoietic SCT using HLA-haploidentical donors in patients with relapse of acute leukaemia after a first allogeneic transplantation. Bone Marrow Transplant. 49 (2014), 895–901.
20. [20] Tischer, J., Engel, N., Fritsch, S., Prevalsek, D., Hubmann, M., Schulz, C., et al. Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings. Ann. Hematol. 94 (2015), 1677–1688.
21. [21] Zoellner, A.K., Fritsch, S., Prevalsek, D., Engel, N., Hubmann, M., Reibke, R., et al. Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma. Bone Marrow Transplant. 50 (2015), 679–684.
22. [22] Kolb, H.-J., Bigalke, I., Simoes, B., Falk, C., Tischer, J., Hill, W., et al. CD6-depleted mobilized stem cells for modification of HVG and GVH reactions after HLA-haploidentical marrow transplantation. Blood, 104, 2004, 978.
23. [23] Heim, A., Ebnet, C., Harste, G., Pring-Akerblom, P., Rapid and quantitative detection of human adenovirus DNA by real-time PCR. J. Med. Virol. 70 (2003), 228–239.
24. [24] Matthes-Martin, S., Feuchtinger, T., Shaw, P.J., Engelhard, D., Hirsch, H.H., Cordonnier, C., et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transpl. Infect. Dis. 14 (2012), 555–563.
25. [25] Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.G., Beatty, P., Hows, J., et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 15 (1995), 825–828.
26. [26] Bacigalupo, A., Ballen, K., Rizzo, D., Giralt, S., Lazarus, H., Ho, V., et al. Defining the intensity of conditioning regimens: working definitions. Biol. Blood Marrow Transplant. 15 (2009), 1628–1633.
27. [27] Ganepola, S., Gentilini, C., Hilbers, U., Lange, T., Rieger, K., Hofmann, J., et al. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant. 39 (2007), 293–299.
28. [28] De Pauw, B., Walsh, T.J., Donnelly, J.P., Stevens, D.A., Edwards, J.E., Calandra, T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46 (2008), 1813–1821.
29. [29] Feuchtinger, T., Richard, C., Joachim, S., Scheible, M.H., Schumm, M., Hamprecht, K., et al. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J. Immunother. 31 (2008), 199–206.
30. [30] Fischer, S.A., Emerging viruses in transplantation: there is more to infection after transplant than CMV and EBV. Transplantation 86 (2008), 1327–1339.
31. [31] Gratwohl, A., Baldomero, H., Schmid, O., Horisberger, B., Bargetzi, M., Urbano-Ispizua, A., Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003. Bone Marrow Transplant. 36 (2005), 575–590.
32. [32] Flomenberg, P., Babbitt, J., Drobyski, W.R., Ash, R.C., Carrigan, D.R., Sedmak, G.V., et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J. Infect. Dis. 169 (1994), 775–781.
33. [33] Baldwin, A., Kingman, H., Darville, M., Foot, A.B., Grier, D., Cornish, J.M., et al. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. Bone Marrow Transplant. 26 (2000), 1333–1338.
34. [34] Howard, D.S., Phillips, I.G., Reece, D.E., Munn, R.K., Henslee-Downey, J., Pittard, M., et al. Adenovirus infections in hematopoietic stem cell transplant recipients. Clin. Inf. Dis. 29 (1999), 1494–1501.
35. [35] Parody, R., Martino, R., Rovira, M., Vazquez, L., Vazquez, M.J., de la Camara, R., et al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol. Blood Marrow Transplant. 12 (2006), 734–748.
36. [36] Ciurea, S.O., Mulanovich, V., Saliba, R.M., Bayraktar, U.D., Jiang, Y., Bassett, R., et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 18 (2012), 1835–1844.
37. [37] Luznik, L., O'Donnell, P.V., Symons, H.J., Chen, A.R., Leffell, M.S., Zahurak, M., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol. Blood Marrow Transplant. 14 (2008), 641–650.
38. [38] Crocchiolo, R., Bramanti, S., Vai, A., Sarina, B., Mineri, R., Casari, E., et al. Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. Transpl. Infect. Dis. 17 (2015), 242–249.
39. [39] Leen, A.M., Myers, G.D., Sili, U., Huls, M.H., Weiss, H., Leung, K.S., et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 12 (2006), 1160–1166.
40. [40] Jeulin, H., Salmon, A., Bordigoni, P., Venard, V., Diagnostic value of quantitative PCR for adenovirus detection in stool samples as compared with antigen detection and cell culture in haematopoietic stem cell transplant recipients. Clin. Microbiol. Infect. 17 (2011), 1674–1680.
41. [41] Vabret, A., Gouarin, S., Joannes, M., Barranger, C., Petitjean, J., Corbet, S., et al. Development of a PCR-and hybridization-based assay (PCR Adenovirus Consensus) for the detection and the species identification of adenoviruses in respiratory specimens. J. Clin. Virol. 31 (2004), 116–122.
42. [42] Sivaprakasam, P., Carr, T.F., Coussons, M., Khalid, T., Bailey, A.S., Guiver, M., et al. Improved outcome from invasive adenovirus infection in pediatric patients after hemopoietic stem cell transplantation using intensive clinical surveillance and early intervention. J. Pediatr. Hematol. Oncol. 29 (2007), 81–85.
43. [43] Echavarria, M., Forman, M., van Tol, M.J., Vossen, J.M., Charache, P., Kroes, A.C., Prediction of severe disseminated adenovirus infection by serum PCR. Lancet 358 (2001), 384–385.
44. [44] Lion, T., Kosulin, K., Landlinger, C., Rauch, M., Preuner, S., Jugovic, D., et al. Monitoring of adenovirus load in stool by real-time PCR permits early detection of impending invasive infection in patients after allogeneic stem cell transplantation. Leukemia 24 (2010), 706–714.
45. [45] Walls, T., Hawrami, K., Ushiro-Lumb, I., Shingadia, D., Saha, V., Shankar, A.G., Adenovirus infection after pediatric bone marrow transplantation: is treatment always necessary?. Clin. Infect. Dis. 40 (2005), 1244–1249.